Issue 74

COMPASS Pathways and COMP360 psilocybin therapy

At the end of 2021, UK-based COMPASS Pathways shared positive results from its Phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD).

The study was the largest ever conducted with the psychedelic medicine, with 233 patients included at 22 sites across Europe and North America.

The trial demonstrated that patients who received a single 25mg dose of COMPASS’s proprietary psilocybin formulation, COMP360, with psychological support, experienced a significant reduction in depressive-symptom severity after three weeks, with a rapid and sustained response lasting the 12-week duration of the trial.

To discuss the study, which COMPASS hopes will lead to COMP360 psilocybin therapy’s regulatory approval, PSYCH spoke with the company’s Chief Medical Officer, Dr Guy Goodwin.

THE CENTRE FOR MENTAL HEALTH RESEARCH AND INNOVATION OPENS IN THE UK

King’s College London, SLaM NHS Foundation Trust and COMPASS partner to accelerate psychedelic research.

WHY DR. BRONNER'S IS OFFERING KETAMINE THERAPY TO ITS EMPLOYEES

Dr. Bronner’s President Michael Bronner spoke with Fast Company on his experiences with ketamine therapy.

BUSINESS AND INVESTMENT

MindMed announces 2021 financial results.

atai Life Sciences reports 2021 financial results.

Inside the brave new world of psychedelic medicine.

Four reasons why psychedelic medicines could change mental health.

Why microdosing is gaining momentum in Australia.

PSYCH Symposium: London 2022

PSYCH Symposium brings leading figures from policy, science and business together to shape the future of psychedelic healthcare in Europe.

Speakers include:

Daniel Karlin – Chief Medical Officer, MindMed
Benjamin Lightburn – CEO, Filament Health
Cosmo Feilding Mellen – CEO, Beckley Psytech

Secure your ticket today to connect with industry influencers and learn from the sector’s thought leaders as we expedite access to psychedelic medicine.

For partnership opportunities, please visit the website.

Ticket registration

SCIENCE AND RESEARCH

What the science says about microdosing.

Can psilocybin be used to treat racial trauma?

Study shows potential for psilocybin in relieving depression.

The promise of psychedelic medicines for health and wellness.

REGULATION AND LEGISLATION

Hazel Park, Michigan, decriminalises entheogenic plants.

Georgia lawmakers approve bill to create psychedelic study committee.

Michigan activists collecting signatures for legalisation initiative.

Hawaiian psilocybin bill amended to seek federal approval.

Washington State’s outlook for psychedelic healthcare.